Osteoclast differentiation inhibitors: a patent review (2008 – 2012)

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.23, Iss.12, 2013-12, pp. : 1591-1610

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glycogen phosphorylase inhibitors: a patent review (2008 - 2012)

By Gaboriaud-Kolar Nicolas Skaltsounis Alexios-Leandros

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 8, 2013-08 ,pp. : 1017-1032

Informa Healthcare

Access to resources Recommend Favorite

Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 – 2012)

By Dolušić Eduard Frédérick Raphaël

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 10, 2013-10 ,pp. : 1367-1381

Informa Healthcare

Access to resources Recommend Favorite

Sulfonamides: a patent review (2008 – 2012)

By Carta Fabrizio Scozzafava Andrea Supuran Claudiu T

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 7, 2012-07 ,pp. : 747-758

Informa Healthcare

Access to resources Recommend Favorite

AT1 antagonists: a patent review (2008 – 2012)

By Mavromoustakos Thomas Agelis George Durdagi Serdar

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 11, 2013-11 ,pp. : 1483-1494

Informa Healthcare

Access to resources Recommend Favorite

Secondary and tertiary sulfonamides: a patent review (2008 – 2012)

By Scozzafava Andrea Carta Fabrizio Supuran Claudiu T

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 2, 2013-02 ,pp. : 203-213

Informa Healthcare

Access to resources Recommend Favorite